Aggressive immunosuppression minimization reduces graft loss following diagnosis of BK virus-associated nephropathy: A comparison of two reduction strategies

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 6, 2008, Pages 1812-1819

  Weiss, Andrew S ^a   Gralla, Jane ^a   Chan, Larry ^a   Klem, Patrick ^a   Wiseman, Alexander C ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; BK VIRUS; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NEPHRITIS; PATHOGENICITY; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; VIROLOGY; VIRUS INFECTION;

ADULT; AGED; ANTIVIRAL AGENTS; BK VIRUS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NEPHRITIS; POLYOMAVIRUS INFECTIONS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 58149333515     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05691207     Document Type: Article

References (29)

1. Purighalla R, Shapiro R, McCauley J, Randhawa P: BK virus infection in a kidney allograft diagnosed by needle biopsy. Am J Kidney Dis 26: 671-673, 1995
2. Mathur VS, Olson JL, Darragh TM, Yen TS: Polyomavirus-induced interstitial nephritis in two renal transplant recipients: case reports and review of the literature. Am J Kidney Dis 29: 754-758, 1997
3. Randhawa PS, Finkelstein S, Scantlebury V, Shapiro R, Vivas C, Jordan M, Picken MM, Demetris AJ: Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 67: 103-109, 1999
4. Hirsch HH, Brennan DC, Drachenberg CB, Ginevri F, Gordon J, Limaye AP, Mihatsch MJ, Nickeleit V, Ramos E, Randhawa P, Shapiro R, Steiger J, Suthanthiran M, Trofe J: Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 79: 1277-1286, 2005
5. Trofe J, Hirsch HH, Ramos E: Polyomavirus-associated nephropathy: update of clinical management in kidney transplant patients. Transpl Infect Dis 8: 76-85, 2006
6. Ramos E, Drachenberg CB, Portocarrero M, Wali R, Klassen DK, Fink JC, Farney A, Hirsch H, Papadimitriou JC, Cangro CB, Weir MR, Bartlett ST: BK virus nephropathy diagnosis and treatment: experience at the University of Maryland Renal Transplant Program. Clin Transpl 143-153, 2002
7. Nickeleit V, Klimkait T, Binet IF, Dalquen P, Del Zenero V, Thiel G, Mihatsch MJ, Hirsch HH: Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med 342: 1309-1315, 2000
8. Randhawa P, Ho A, Shapiro R, Vats A, Swalsky P, Finkelstein S, Uhrmacher J, Weck K: Correlates of quantitative measurement of BK polyomavirus (BKV) DNA with clinical course of BKV infection in renal transplant patients. J Clin Microbiol 42: 1176-1180, 2004
9. Brennan DC, Agha I, Bohl DL, Schnitzler MA, Hardinger KL, Lockwood M, Torrence S, Schuessler R, Roby T, Gaudreault-Keener M, Storch GA: Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 5: 582-594, 2005
10. Kadambi PV, Josephson MA, Williams J, Corey L, Jerome KR, Meehan SM, Limaye AP: Treatment of refractory BK virus-associated nephropathy with cidofovir. Am J Transplant 3: 186-191, 2003
11. Vats A, Shapiro R, Singh Randhawa P, Scantlebury V, Tuzuner A, Saxena M, Moritz ML, Beattie TJ, Gonwa T, Green MD, Ellis D: Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation 75: 105-112, 2003
12. Kuypers DR, Vandooren AK, Lerut E, Evenepoel P, Claes K, Snoeck R, Naesens L, Vanrenterghem Y: Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transplant 5: 1997-2004, 2005
13. Williams JW, Javaid B, Kadambi PV, Gillen D, Harland R, Thistlewaite JR, Garfinkel M, Foster P, Atwood W, Millis JM, Meehan SM, Josephson MA: Leflunomide for polyomavirus type BK nephropathy. N Engl J Med 352: 1157-1158, 2005
14. Josephson MA, Gillen D, Javaid B, Kadambi P, Meehan S, Foster P, Harland R, Thistlethwaite RJ, Garfinkel M, Atwood W, Jordan J, Sadhu M, Millis MJ, Williams J: Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation 81: 704-710, 2006
15. Faguer S, Hirsch HH, Kamar N, Guilbeau-Frugier C, Ribes D, Guitard J, Esposito L, Cointault O, Modesto A, Lavit M, Mengelle C, Rostaing L: Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. Transpl Int 20: 962-969, 2007
16. Thamboo TP, Jeffery KJ, Friend PJ, Turner GD, Roberts IS: Urine cytology screening for polyoma virus infection following renal transplantation: the Oxford experience. J Clin Pathol 60: 927-930, 2007
17. Sener A, House AA, Jevnikar AM, Boudville N, McAlister VC, Muirhead N, Rehman F, Luke PP: Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. Transplantation 81: 117-120, 2006
18. Drachenberg CB, Papadimitriou JC, Hirsch HH, Wali R, Crowder C, Nogueira J, Cangro CB, Mendley S, Mian A, Ramos E: Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant 4: 2082-2092, 2004
19. Drachenberg CB, Papadimitriou JC, Ramos E: Histologic versus molecular diagnosis of BK polyomavirus-associated nephropathy: a shifting paradigm? Clin J Am Soc Nephrol 1: 374-379, 2006
20. Vasudev B, Hariharan S, Hussain SA, Zhu YR, Bresnahan BA, Cohen EP: BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients. Kidney Int 68: 1834-1839, 2005
21. Wali RK, Drachenberg C, Hirsch HH, Papadimitriou J, Nahar A, Mohanlal V, Brisco MA, Bartlett ST, Weir MR, Ramos E: BK virus-associated nephropathy in renal allograft recipients: rescue therapy by sirolimus-based immunosuppression. Transplantation 78: 1069-1073, 2004
22. Benavides CA, Pollard VB, Mauiyyedi S, Podder H, Knight R, Kahan BD: BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation 84: 83-88, 2007
23. Mengel M, Marwedel M, Radermacher J, Eden G, Schwarz A, Haller H, Kreipe H: Incidence of polyomavirus-nephropathy in renal allografts: influence of modern immunosuppressive drugs. Nephrol Dial Transplant 18: 1190-1196, 2003
24. Wadei HM, Rule AD, Lewin M, Mahale AS, Khamash HA, Schwab TR, Gloor JM, Textor SC, Fidler ME, Lager DJ, Larson TS, Stegall MD, Cosio FG, Griffin MD: Kidney transplant function and histological clearance of virus following diagnosis of polyomavirus-associated nephropathy (PVAN). Am J Transplant 6: 1025-1032, 2006
25. Smith JM, Dharnidharka VR, Talley L, Martz K, McDonald RA: BK virus nephropathy in pediatric renal transplant recipients: an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry. Clin J Am Soc Nephrol 2: 1037-1042, 2007
26. Hirsch HH, Knowles W, Dickenmann M, Passweg J, Klimkait T, Mihatsch MJ, Steiger J: Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 347: 488-496, 2002
27. Andreoni KA, Brayman KL, Guidinger MK, Sommers CM, Sung RS: Kidney and pancreas transplantation in the United States, 1996-2005. Am J Transplant 7: 1359-1375, 2007
28. Oberbauer R, Kreis H, Johnson RW, Mota A, Claesson K, Ruiz JC, Wilczek H, Jamieson N, Henriques AC, Paczek L, Chapman J, Burke JT: Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 76: 364-370, 2003
29. Ekberg H, Grinyo J, Nashan B, Vanrenterghem Y, Vincenti F, Voulgari A, Truman M, Nasmyth-Miller C, Rashford M: Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 7: 560-570, 2007